Brief report: Social disability in autism spectrum disorder: Results from research units on pediatric psychopharmacology (RUPP) autism network trials

Journal of Autism and Developmental Disorders

Volumn 43, Issue 3, 2013, Pages 739-746

  Scahill, Lawrence ^a,j   Hallett, Victoria ^a,k   Aman, Michael G ^b   McDougle, Christopher J ^c,i   Eugene Arnold, L ^b   McCracken, James T ^d   Tierney, Elaine ^e   Deng, Yanhong ^f   Dziura, James ^g   Vitiello, Benedetto ^h  

^a YALE UNIVERSITY SCHOOL OF NURSING   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f YALE UNIVERSITY   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

ⁱ INDIANA UNIVERSITY   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Aberrant Behavior Checklist; Autism; Research Units on Pediatric Psychopharmacology (RUPP) Autism Network; Risperidone; Social disability; Social withdrawal

Indexed keywords

PLACEBO; RISPERIDONE;

ABERRANT BEHAVIOR CHECKLIST SOCIAL WITHDRAWAL SCALE; ADOLESCENT; ARTICLE; ASPERGER SYNDROME; AUTISM; CHILD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PATIENT EDUCATION; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SCHOOL CHILD; SOCIAL DISABILITY; TRAINING;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RESEARCH DESIGN; RISPERIDONE; SOCIAL BEHAVIOR; SOCIAL PERCEPTION; TREATMENT OUTCOME;

EID: 84878850445     PISSN: 01623257     EISSN: 15733432     Source Type: Journal    
DOI: 10.1007/s10803-012-1689-3     Document Type: Article

References (28)

1. Aman, M. G.; McDougle, C. J.; Scahill, L.; Handen, B.; Arnold, L. E.; Johnson, C.; et al. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(12), 1143-1154.
2. Aman, M. G.; Singh, N. N.; Stewart, A. W.; Field, C. J. (1985). Psychometric characteristics of the Aberrant Behavior Checklist. American Journal of Mental Deficiency, 89, 492-502.
3. Autism Speaks. (2011). Autism speaks announces a major effort to develop new effective medical treatments for people with ASD. http://blog.autismspeaks. org/2011/02/15/science-effective-medical-treatments. Accessed September 18, 2012.
4. Brown, E. C.; Aman, M. G.; Havercamp, S. M. (2002). Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist - Community for young people in special education. Research in Developmental Disabilities, 23, 45-60.
5. Carter, A. S.; Volkmar, F. R.; Sparrow, S. S.; et al. (1998). The Vineland Adaptive Behavior Scales: Supplementary norms for individuals with autism. Journal of Autism and Developmental Disorders, 28(4), 287-302.
6. Centers for Disease Control and Prevention. (2012). Prevalence of Autism Spectrum Disorders-Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. Morbidity Mortality Weekly Report, 61(3), 2-19.
7. Dolen, G.; Carpenter, R. L.; Ocain, T. D.; Bear, M. F. (2010). Mechanism-based approaches to treating fragile X. Pharmacology & Therapeutics, 127(2010), 78-93.
8. Gadow, K. D.; DeVincent, C.; Schneider, J. (2008). Predictors of psychiatric symptoms in children with an Autism Spectrum Disorder. Journal of Autism and Developmental Disorders, 38, 1710-1720.
9. Guy, W. (1976). Clinical global impressions. In ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health.
10. Interagency Autism Coordinating Committee. (2011). IACC strategic plan for autism spectrum disorder research. Retrieved from the Department of Health and Human Services Interagency Autism Coordinating Committee website at http://iacc.hhs.gov/strategic-plan/2011/index.shtml (2011 Jan).
11. Jacquemont, S.; Curie, A.; des Portes, V.; Torrioli, M. G.; Berry-Kravis, E.; Hagerman, R. J.; et al. (2011). Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Science Translational Medicine, 3(64), 64ra1.
12. King, B. H.; Hollander, E.; Sikich, L.; McCracken, J. T.; Scahill, L.; Bregman, J. D.; et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behaviour: citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583-590.
13. Lord, C.; Rutter, M.; Le Couteur, A. (1994). Autism diagonostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24, 659-685.
14. Lecavalier, L. (2006). Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders, 36, 1101-1114.
15. Levy, S. E.; Mandell, D. S.; Schultz, R. T. (2007). Autism. Lancet, 374(9701), 1627-1638 (Erratum appears in Lancet. 2011 Oct 29;378(9802):1546).
16. Marcus, R. N.; Owen, R.; Kamen, L.; et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110-1119.
17. O' Roak, B. J.; State, M. W. (2008). Autism genetics: Strategies, challenges, and opportunities. Autism Research, 1(1), 4-17.
18. Owen, R.; Sikich, L.; Marcus, R.; et al. (2009). A multicenter, double-blind, randomized, placebo controlled, flexible-dose, parallel-group study of aripiprazole in the treatment of irritability in children and adolescents (6-17 years) with autistic disorder. Pediatrics, 124, 1533-1540.
19. Posey, D. J.; Erickson, C. A.; McDougle, C. J. (2008). Developing drugs for core social and communication impairment in autism. Child & Adolescent Psychiatric Clinics of North America, 17(4), 787-801.
20. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266-1274.
21. Robinson, E. B.; Koenen, K. C.; McCormick, M. C.; Munir, K.; Hallett, V.; Happe, F.; et al. (2011). Evidence that autistic traits show the same etiology in the general population and at the quantitative extremes (5%, 2.5%, and 1%). Archives of General Psychiatry, 68(11), 1113-1121.
22. RUPP Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. NEJM, 347(5), 314-321.
23. Scahill, L.; McDougle, C. J.; Aman, M. G.; Johnson, C.; Handen, B.; Bearss, K.; et al. (2012). Effects of risperidone and parent training on adaptive functioning in children with a pervasive developmental disorders and serious behavioral problems. Journal of the American Academy of Child and Adolescent Psychiatry, 51(2), 136-146.
24. Shea, S.; Turgay, A.; Carrol, A.; et al. (2004). Risperidone in the treatment of disruptive behavioural symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634-e641.
25. Sparrow, S. S.; Balla, D. A.; Cicchetti, D. V. (1984). Vineland adaptive behavior scales. Circle Pines, MN: American Guidance Service.
26. Sukhodolsky, D. G.; Scahill, L.; Gadow, K. D.; Arnold, L. E.; Aman, M. G.; McDougle, C. J.; et al. (2008). Parent-rated anxiety symptoms in children with pervasive developmental disorders: Frequency and association with core autism symptoms and cognitive functioning. Journal of Abnormal Child Psychology, 36(1), 117-128.
27. US Food and Drug Administration. (2006). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims. Available from: ttp:// www.Fda.Gov/Cder/Guidance/5460dft.Pdf [Accessed May 4, 2007]. Federal Register: February 3, 2006, Vol. 71. Number (23) Docket no. 2006D-0044.
28. Veenstra-VanderWeele, J.; King, B.; Erickson, C.; Ginsberg, L.; Melman, R.; Scahill, L.; et al. (2011). An open label trial of arbaclofen in autism spectrum disorder shows improvements in multiple symptom domains. Poster presentation at NCDEU. Spring, 2011.